pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
KRAS · news · pharmadog
← back to KRAS
News · KRAS
170
stories
Sep 15, 26
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
Sep 14, 26
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
Sep 11, 26
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
biopharma dive
Sep 11, 26
The future of RAS inhibitors
fiercebiotech
Sep 10, 26
BridgeBio Oncology slides as it tightens the scope of its KRAS program
endpoints
Sep 9, 26
CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
fiercebiotech
Sep 4, 26
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
biopharma dive
Sep 3, 26
GSK wagers up to $1.3B on a different kind of cancer drug
biopharma dive
Sep 3, 26
RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer
biospace
Sep 3, 26
STAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more
stat
Sep 3, 26
GSK inks another Asia alliance, betting up to $1.3B for HUTCHMED’s cancer therapy
biospace
Sep 3, 26
GSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfront
endpoints
Sep 3, 26
GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset
fiercebiotech
Aug 27, 26
What’s in Merck and Moderna’s cancer vaccine algorithm?
stat
Aug 27, 26
RevMed could become ‘next oncology titan’ with Rasonque nod
biospace
Aug 26, 26
Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
biopharma dive
Aug 26, 26
RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug
biospace
Aug 26, 26
FDA approves Revolution Medicines' pancreatic cancer drug
endpoints
Aug 26, 26
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
fda press
Aug 26, 26
FDA greenlights Revolution Medicines' pancreatic cancer gamechanger
fiercebiotech
Aug 26, 26
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
fiercebiotech
Aug 26, 26
Hansoh heralds China’s move from ‘follower’ to ‘frontrunner’ in biopharma race
fiercebiotech
Aug 25, 26
After some ‘tough years,’ Frontier’s CEO is ramping up ambitions for precision med platform
fiercebiotech
Aug 20, 26
STAT+: One of the most consequential years for cancer treatment, ever
stat
Aug 13, 26
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
Aug 13, 26
PDS halts work on phase 3 cancer therapy to focus on colorectal contender
fiercebiotech
Aug 10, 26
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win
endpoints
Aug 7, 26
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
Aug 3, 26
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
Jul 29, 26
Incyte cuts early-stage cancer drug to focus on next-gen programs
biospace
← prev
page 3 of 6
next →